The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?

References

• Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br. J. Gen. Pract.47, 285–289 (1997).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol.82(8A), 2N–9N (1998).
   PubMed Web of Science ®Google Scholar
• Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch. Intern. Med.154, 1449–1457 (1994).
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly; the Framingham Heart Study. Arch. Intern. Med.147, 1561–1564 (1987).
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population based cohort. The Framingham Heart Study. JAMA271, 840–844 (1994).
   PubMed Web of Science ®Google Scholar
• Petty GW, Khandheria BK, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Predictors of cerebrovascular events and death among patients with valvular heart disease: a population-based study. Stroke31, 2628–2635 (2000).
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation114, e257–e354 (2006).
   PubMed Web of Science ®Google Scholar
• Singer DE, Albers GW, Dalen JE et al.; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 8th edition. Chest133, 546S–592S (2008).
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA); Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart. J.31(19), 2369–2429 (2010).
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results of the National Registry of Atrial Fibrillation. JAMA285, 2864–2870 (2001).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Massaro JM, Levy D et al. A risk score for predicting stroke or death in individuals with new onset atrial fibrillation in the community: the Framingham Heart Study. JAMA290, 1049–1056 (2003).
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I–III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) investigators. Stroke30, 1223–1229 (1999).
   PubMed Web of Science ®Google Scholar
• Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with non-valvular atrial fibrillation. Stroke39, 1901–1910 (2008).
   PubMed Web of Science ®Google Scholar
• Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb. Haemost.101, 367–372 (2009).
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest137, 263–272 (2010).
   PubMed Web of Science ®Google Scholar
• Lip GYH, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am. J. Med.123, 484–488 (2010).
   PubMed Web of Science ®Google Scholar
• Pisters R, van Oostenbrugge RJ, Knottnerus IL et al. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace12, 779–784 (2010).
   PubMed Web of Science ®Google Scholar
• Devereaux PJ, Anderson DR, Gardner MJ et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Br. Med. J.323, 1218–1222 (2001).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Hart RG et al.; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med.360, 2066–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Hylek EM, D’Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke37, 1075–1080 (2006).
   PubMed Web of Science ®Google Scholar
• Devereaux PJ, Ghali WA, Gibson NE et al. Physicians’ recommendations for patients who undergo noncardiac surgery. Clin. Invest. Med.23, 116–123 (2000).
   PubMed Web of Science ®Google Scholar
• Abdelhafiz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin. Ther.26, 1470–1478 (2004).
   PubMed Web of Science ®Google Scholar
• Wehinger C, Stöllberger C, Länger T, Schneider B, Finsterer J. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke32, 2246–2252 (2001).
   PubMed Web of Science ®Google Scholar
• Hughes M, Lip GYH; Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM100, 599–607 (2007).
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y et al. Death and disability from warfarin-associated intracranial and extracranial haemorrhages. Am. J. Med.120, 700–705 (2007).
   PubMed Web of Science ®Google Scholar
• Kuijer PMM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch. Intern. Med.159, 457–460 (1999).
   PubMed Web of Science ®Google Scholar
• Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am. J. Med.105, 91–99 (1998).
   PubMed Web of Science ®Google Scholar
• Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am. Heart J.151, 713–719 (2006).
   PubMed Web of Science ®Google Scholar
• Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest130, 1390–1396 (2006).
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest DOI: 10.1378/chest.10-0134 (2010) (Epub ahead of print).
   Google Scholar
• Zhu Y, Shennan M, Reynolds KK et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem.53, 1199–1205 (2007).
   PubMed Web of Science ®Google Scholar
• Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis25, 45–51 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson JL, Horne BD, Stevens SM et al.; Couma-Gen Investigators. Randomized trial of genotype guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation116, 2563–2570 (2007).
   PubMed Web of Science ®Google Scholar
• Leey JA, McCabe S, Koch JA, Miles TP. Cost–effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. Am. J. Geriatr. Pharmacother.7, 197–203 (2009).
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Barker L, Kim YK et al. Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thromb. Res.125, e128–e131 (2010).
   PubMed Web of Science ®Google Scholar
• Wan Y, Heneghan C, Perera R et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ. Cardiovasc. Qual. Outcomes1, 84–91 (2008).
   PubMed Web of Science ®Google Scholar
• Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb. Res.124, 37–41 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S et al. and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.361, 1139–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N. Engl. J. Med.347, 969–974 (2002).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, O’Donnell M, Yusuf S et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am. Heart J.159, 348–353 (2010).
   PubMed Web of Science ®Google Scholar
• ROCKET AF Study Investigators. Rivaroxaban-Once Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am. Heart J.159, 340–347 (2010).
   PubMed Web of Science ®Google Scholar
• Ostermayer SH, Reisman M, Kramer PH et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J. Am. Coll. Cardiol.46, 9–14 (2005).
   PubMed Web of Science ®Google Scholar
• Block PC, Burstein S, Casale PN et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc. Interv.2, 594–600 (2009).
   PubMed Web of Science ®Google Scholar
• Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet374(9689), 534–542 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Crijns HJ, Torp-Pedersen C et al. ATHENA Investigators. Analysis of stroke in ATHENA: a Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter. Circulation120, 1174–1180 (2009).
   PubMed Web of Science ®Google Scholar
• Tzou WS, Marchlinski FE, Zado ES et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ. Arrhythm. Electrophysiol.3, 237–242 (2010).
   PubMed Web of Science ®Google Scholar
• Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am. Heart J.156, 57–64 (2008).
   PubMed Web of Science ®Google Scholar